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Indoxyl sulfate (IS)-mediated 
immune dysfunction provokes 
endothelial damage in patients 
with end-stage renal disease 
(ESRD)
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Hee Tae Yu6, Min Chang Kim  7, Joo-Youn Cho  7, Chan Joo Lee8, Hyeon Chang Kim  9, 
Sungha Park6 & Won-Woo Lee  1,2,4,5,10
Progressive renal failure causes uremia-related immune dysfunction, which features a chronic 
inflammatory milieu. Given the central role of end-stage renal disease (ESRD)-related immune 
dysfunction in the pathogenesis of cardiovascular diseases (CVDs), much attention has been focused 
on how uremic toxins affect cellular immunity and the mechanisms underlying pathogenesis of 
atherosclerosis in ESRD patients. Here, we investigated the characteristics of monocytes and CD4+ T 
cells in ESRD patients and the immune responses induced by indoxyl sulfate (IS), a key uremic toxin, 
in order to explore the pathogenic effects of these cells on vascular endothelial cells. In ESRD patients, 
monocytes respond to IS through the aryl hydrocarbon receptor (AhR) and consequently produce 
increased levels of TNF-α. Upon stimulation with TNF-α, human vascular endothelial cells produce 
copious amounts of CX3CL1, a chemokine ligand of CX3CR1 that is highly expressed on CD4+CD28−T 
cells, the predominantly expanded cell type in ESRD patients. A migration assay showed that 
CD4+CD28− T cells were preferentially recruited by CX3CL1. Moreover, activated CD4+CD28− T cells 
exhibited cytotoxic capability allowing for the induction of apoptosis in HUVECs. Our findings suggest 
that in ESRD, IS-mediated immune dysfunction may cause vascular endothelial cell damage and thus, 
this toxin plays a pivotal role in the pathogenesis of CVD.
Progressive loss of renal function is strongly associated with aberrant immune responses. Uremia accompany-
ing renal failure causes immune dysfunction characterized by the paradoxical coexistence of immune activa-
tion and immune suppression2, 3. In patients with ESRD, the elevated risk of cardiovascular diseases is closely 
linked to uremia-related immune activation, such as hypercytokinemia and inflammation. On the other hand, the 
impaired immune responses in these patients lead to increased susceptibility to infections, poor adaptive immune 
responses to standard vaccination procedures, and even enhanced risk of malignancies4–6. Of importance, the two 
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leading causes of death in patients with ESRD are cardiovascular disease (CVD) and infection, and both patho-
logic processes are closely associated with uremia-related immune dysfunction4, 7.
The retention of uremic toxins and cytokines in patients with chronic kidney diseases (CKD) plays a critical 
role in the generation of oxidative stress and the proinflammatory milieu, which likely affect the composition and 
function of the cellular immune system8–10. In fact, it has been reported that CD14+CD16+ monocytes and CD4+ 
T cells lacking expression of the co-stimulatory molecule CD28 (hereafter, CD4+CD28− T cells) are markedly 
expanded in the patients with ESRD11–16. A significant increase in both cell subsets is also observed in patients 
with various chronic inflammatory disorders including autoimmunity, further implicating their pathogenic 
roles17–21. Given that CVD is broadly recognized as a chronic immune-mediated inflammatory disease, attention 
has recently been focused on the contribution of expanded CD14+CD16+ monocytes and CD4+CD28− T cells to 
the pathogenesis of this disease in ESRD patients22.
Among over 100 uremic toxins identified23, the presence of indoxyl sulfate (IS) and p-cresyl sulfate (PCS), 
originating from microbial fermentation of proteins in the gut, are closely associated with adverse outcomes 
in patients with renal failure. The dietary amino acids tryptophan and tyrosine are bacterially metabolized into 
indoles and p-cresol in the colon, respectively. After absorption, these are further converted into IS and PCS in the 
liver24. Patients with CKD show markedly higher serum IS and PCS levels than do healthy individuals. Together 
these toxins are largely responsible for progression of CKD and the development of CKD-related complications 
such as CVD25. A number of studies have focused primarily on IS-mediated endothelial dysfunction in order to 
elucidate its pathogenic role in CVD26, 27. Although the concept of uremia-related immune dysfunction is now 
well appreciated, little is known about the impact of IS on the cellular immune system and chronic inflammatory 
responses that can accelerate development and progression of CVD in ESRD patients. Thus, we hypothesized that 
IS, a major uremic toxin, causes aberrant responses of the cellular immune system and that these immunological 
defects contribute to adverse effects on vascular endothelial cells.
Here we demonstrate that ESRD patients have significantly higher serum IS and PCS levels compared 
with those of healthy controls. Moreover, IS, but not PCS, induces secretion of TNF-α by human monocytes 
through the aryl hydrocarbon receptor (AhR), and this induction is dramatically repressed by treatment with 
AhR inhibitors or by knockdown using AhR-targeted siRNA. Upon stimulation with TNF-α, human endothe-
lial cells predominantly produce CX3CL1, a specific chemokine ligand of CX3CR1, which is highly expressed 
on CD4+CD28− T cells. Of importance, ESRD patients have a markedly higher frequency of circulating cytol-
ytic CD4+CD28− T cells, which are significantly expanded under chronic exposure to TNF-α when compared 
with age-matched healthy controls (HCs). A migration assay revealed that CD4+CD28− T cells are preferentially 
recruited by CX3CL1. Moreover, CD4+CD28− T cells stimulated through their T cell receptors (TCRs) induced 
apoptosis of human endothelial cells, suggesting that IS-mediated immune dysfunction could be associated with 
the development and accelerated progression of CVD in patients with renal failure.
Results
Indoxyl sulfate (IS), a uremic toxin, induces production of TNF-α by human monocytes. 
Retained uremic toxins are believed to be an underlying cause of the proinflammatory cytokine milieu seen in 
ESRD1. It has been demonstrated that protein-bound uremic toxins, indoxyl sulfate (IS) and p-cresyl sulfate 
(PCS), originating from microbial fermentation of proteins in the gut, are responsible for adverse outcomes in 
patients with renal failure28, 29. As expected, the concentrations of IS and PCS in plasma of ESRD patients (clinical 
characteristics of patients and HCs are presented in Table 1) were greatly higher than those in HCs (Fig. 1A, HC 
1.87 ± 0.21 μM vs. ESRD 102.44 ± 6.26 μM for IS, p < 0.0001; HC 15.04 ± 4.7 μM vs. ESRD 185.41 ± 14.99 μM for 
PCS, p < 0.0001). The maximal levels of IS and PCS in ESRD patients were over 300 μM and 600 μM, respectively.
Aberrant functional and phenotypical features of monocytes have been well reported in ESRD patients1. 
Consistent with previous studies14, 15, the frequencies of proinflammatory CD16+ monocytes as well as total 
monocytes (defined as HLA-DR+CD14dim/+ cells) in ESRD patients were significantly increased compared with 
those of HCs (Suppl. Fig. 1A and B). Given the central role of proinflammatory monocytes as drivers of vascular 
inflammation in CVD, we sought to investigate effect of IS and PCS on immune response of monocytes in ESRD.
We first investigated the induction of proinflammatory cytokines by IS and PCS in monocytes, and found 
augmented TNF-α mRNA (6.26-fold increase, Fig. 1B: p < 0.05) after a 24-hour treatment with IS, but not PCS. 
In agreement with the dose-dependent enhancement of its gene expression (Fig. 1C), the amount of TNF-α 
(204.01 ± 55.63 pg/ml) in the monocyte culture supernatant was significantly increased following 48 hours of 
IS treatment compared to the untreated group (95.55 ± 39.99 pg/ml) (Fig. 1D). It should be noted that apoptosis 
was not induced by treatment with the highest concentration (1,000 μM) of IS for 48 hr (data not shown). We also 
confirmed that IS induced increases in IL-1β mRNA in cells and IL-1β protein in supernatants after a 48-hour 
treatment with IS, but not PCS (Suppl. Fig. 2A and B). However, no induction of IL-6 mRNA and its protein was 
observed in monocytes with both IS and PCS treatment (Suppl. Fig. 3).
Consistent with previous reports30, 31, the serum of ESDR patient had significantly increased levels of TNF-α 
compared with those of HCs (Suppl. Fig. 4). To further investigate these findings, we selected patients with the 
top 10 (IShigher-ESRD) and bottom 10 (ISlower-ESRD) patients levels of serum IS, respectively, and pooled their 
sera into high and low groups for further analysis. Monocytes treated with 30% (v/v) of pooled sera for 24 hours 
upregulated TNF-α expression slightly, but significantly (IShigher-ESRD (n = 10; 184.08 ± 44.75 μM of IS) and 
ISlower-ESRD (n = 10; 38.10 ± 8.03 μM of IS)), compared with monocytes treated with pooled sera from HCs 
(n = 9) (Fig. 1E).
Taken together, these findings suggest that IS is involved in the induction of proinflammatory cytokines such 
as TNF-α and IL-1β productions by monocytes.
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IS-induced TNF-α expression is dependent on aryl hydrocarbon receptor (AhR)-mediated 
responses in human monocytes. We next sought to explore how IS affects the inflammatory response of 
monocytes, which exhibit prominent ESRD-related changes. Since IS was recently identified as a potent endoge-
nous ligand for the aryl hydrocarbon receptor (AhR)32, 33, responsiveness to IS was assessed by the expression of 
two genes known to be regulated by this pathway, CYP1A1 and CYP1B1. As shown in Fig. 2A, IS led to markedly 
enhanced expression of CYP1A1 and CYP1B1 mRNAs in monocytes (66.93 ± 15.08-fold increase; p < 0.012 and 
7.45 ± 1.61- fold increase; p < 0.017, respectively). Of note, this induction was 5 to 30 times greater than that seen 
in cells treated with 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a potent AhR agonist. Western blot analysis 
confirmed that AhR was constitutively expressed at high levels by freshly-isolated monocytes (Fig. 2B), suggest-
ing that circulating monocytes may be a major cellular subset responding to IS in the serum of ESRD patients. 
Furthermore, AhR mRNA expression was upregulated in monocytes of ESRD patients compared to that of HCs 
(Fig. 2C). In addition, treatment with pooled sera from ESRD patients (at 30% (v/v) for 24 hr) increased the 
mRNA expression of CYP1B1 in HC monocytes (Fig. 2D; p < 0.05).
To further investigate a role of AhR for IS-induced TNF-α expression, monocytes were stimulated with IS in 
the presence of potent AhR antagonists, α-naphthoflavone (α-NF) or GNF351. As shown in Fig. 3, IS-induced 
TNF-α mRNA and protein expression were significantly inhibited by both α-NF and GNF351 (Fig. 3A–C). 
As expected, α-NF inhibited expression of the AhR responsive gene, CYP1B1, (Fig. 3D), indicating that α-NF 
represses AhR-mediated responses in monocytes. In addition, blocking the AhR-mediated response with GNF351 
completely abrogated the inductions of TNF-α, CYP1B1, and IL-1β by HC monocytes treated with pooled sera 
from ESRD patients (Fig. 3E and F and Suppl. Fig. 5).
Our finding was corroborated by an AhR siRNA (siAhR) knockdown experiment (Fig. 3G–I). Freshly puri-
fied human monocytes were transfected with AhR-targeted siRNA and then treated with IS for 24 hr. siAhR led 
to downregulation of its mRNA expression by approximately 50% compared with cells transfected with control 
ESRD 
(n = 50)
Control 
(n = 28) p-value
Clinical variables
 Age (years) 53.2 ± 12.8 52.9 ± 9.1 0.910
 Male gender 32 (64.0%) 18 (64.3%) 1.000
 CAD 9 (18.0%) 0 (0%) 0.023*
 Hypertension 38 (82.6%) 5 (17.9%) <0.001*
 DM 14 (31.1%) 1 (3.6%) 0.006*
 Dyslipidemia 6 (13.0%) 6 (21.4%) 0.352
 Current Smoker 5 (10.0%) 6 (21.4%) 0.188
 BMI (kg/m2) 23.6 ± 3.4 24.0 ± 2.3 0.566
 SBP (mmHg) 149.4 ± 22.6 119.3 ± 9.5 <0.001*
 DBP (mmHg) 81.7 ± 11.4 77.3 ± 7.9 0.078
 Anuria 35 (70%)
 Hemodialysis 22 (44%)
 Peritoneal dialysis 28 (56%)
 Dialysis duration (year) 5.5 ± 6.3
Laboratory variables
 WBC count (×103/μL) 6.3 ± 2.0 6.1 ± 1.5 0.566
 Hemoglobin (g/dL) 11.0 ± 1.5 14.5 ± 1.8 <0.001*
 Glucose (mg/dL) 102.0 ± 38.9 95.1 ± 17.0 0.380
 Total cholesterol (mg/dL) 157.9 ± 33.4 193.5 ± 29.2 <0.001*
 HDL cholesterol (mg/dL) 46.8 ± 17.3 53.0 ± 12.6 0.105
 Triglyceride (mg/dL) 97.2 ± 51.3 149.3 ± 159.3 0.104
 Uric acid (mg/dL) 6.1 ± 1.6 4.9 ± 1.3 0.002*
 hsCRP (mg/L) 3.1 ± 6.8 1.0 ± 0.9 0.074
 BUN (mg/dL) 58.3 ± 23.6 15.1 ± 4.1 <0.001*
 Creatinine (mg/dL) 10.6 ± 3.7 1.0 ± 0.2 <0.001*
 Albumin (g/dL) 3.9 ± 0.5 4.6 ± 0.2 <0.001*
 Calcium (mg/dL) 9.1 ± 0.7
 Phosphorus (mg/dL) 5.0 ± 1.5
 Calcium-phosphorus 
product (mg2/dL2) 45.6 ± 13.9
Table 1. Clinical characteristics of ESRD patients and healthy control subjects. ESRD, end-stage renal disease; 
CAD, coronary artery disease; DM, diabetes mellitus; BMI, body mass index; BUN, blood urea nitrogen; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; HDL, high-density lipoprotein; 
hsCRP, high-sensitivity C-reactive protein. Data are presented as mean ± SD or n (%). *A p-value < 0.05 was 
considered statistically significant.
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siRNA (siNC) (Fig. 3G). Further, knockdown of AhR resulted in decreased TNF-α and CYP1B1 mRNA expres-
sion at around 50% in response to IS treatment compared to the control siRNA group (Fig. 3H and I).
Increased oxidative stress in patients with uremia is closely related to the pro-inflammatory state of the 
immune system8, 34. To examine whether IS induces ROS production in monocytes and its production affects 
TNF-α induction, we measured ROS production by IS-treated total monocytes. Monocyte significantly enhanced 
ROS production as early as 30 min after treatment with IS and its level increased until 2-hour of treatment (Suppl. 
Fig. 6A). IS-mediated ROS production was partially abrogated by ROS inhibitor NAC (N-acetyl-L-cysteine). Of 
important, AhR antagonist GNF351 had no effect on IS-mediated ROS production in primary monocytes (Suppl. 
Fig. 6B), suggesting that different mechanisms may be involved in increased level of ROS and enhanced produc-
tion of TNF-α by IS-treated monocytes.
Taken together, these findings demonstrate that the AhR-mediated response is responsible for IS-induced 
TNF-α expression in human monocytes.
Human endothelial cells substantially induce CX3CL1 in response to proinflammatory cytokine 
stimulation. Selective recruitment of inflammatory immune cells is a critical step in the pathogenesis of 
cardiovascular diseases35. Because the chemokine CX3CL1 is known to play a cardinal role in plaque formation 
through recruitment of T cells and monocytes36, we investigated whether IS-induced proinflammatory cytokines 
lead to secretion of CX3CL1 by HUVECs. As seen in Fig. 4, CX3CL1 mRNA was immensely upregulated in 
HUVECs following stimulation with TNF-α. We also found that IL-1β induced marked upregulation of CX3CL1 
mRNA in HUVECs (Suppl. Fig. 7). The upregulation of CX3CL1 mRNA in HUVECs was initiated as early as 
Figure 1. Indoxyl sulfate (IS), a uremic toxin, induces production of TNF-α by human monocytes. (A) 
Serum indoxyl sulfate (IS) and p-cresyl sulfate (PCS) levels in ESRD patients (n = 64) and healthy controls 
(n = 15) were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS). (B) Purified 
monocytes were stimulated with 1,000 μM of IS or 500 μM of PCS for 24 hr and then TNF-α mRNA expression 
was analyzed by real-time RT-PCR. (C and D) Purified monocytes were stimulated with IS at the indicated 
concentrations. The expression of TNF-α mRNA was analyzed by real-time RT-PCR after a 24 hr stimulation 
(C) and its protein level was quantified by ELISA at 48 hr post-stimulation (D). (E) Sera were pooled from 
patients with the top 10 (IShigher-ESRD) and bottom 10 (ISlower-ESRD) IS serum concentrations, respectively. As 
a control, sera from healthy controls were pooled. Monocytes isolated from healthy controls were treated with 
30% (v/v) of the indicated sera for 24 hr and TNF-α mRNA expression was analyzed by real-time RT-PCR. 
Expression of β-actin was used as a normalization control. Bar graphs and scatter plot show the mean ± SEM 
of three (B), five to seven (C and D), and four (E) independent experiments. *p < 0.05, **p < 0.01, and 
***p < 0.001 by two-tailed unpaired (A) or paired t-test (B,C,D and E).
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30 minutes and reached a maximum level at 4 hours after TNF-α exposure (Fig. 4A). In addition, CX3CL1 gene 
expression increased in a dose-dependent manner in response to TNF-α with concentrations ranging from 0 to 
10 ng/ml (327.00 ± 18.19-fold increase at 10 ng/ml TNF-α; p < 0.01), as did CX3CL1 protein production; how-
ever, CX3CL1 protein reached a plateau at 5 ng/ml of TNF-α (Fig. 4B and C). To further investigate this finding 
in a more physiological setting, purified monocytes were treated with IS for 48 hr and the culture supernatant 
[henceforth known as monocyte-conditioned media (MCM)] was added to HUVECs for 4 hr. Treatment of 
HUVECs with IS-treated MCM resulted in the marked upregulation of CX3CL1 mRNA, which was completely 
inhibited by TNF-α neutralizing antibody (Fig. 4D). In contrast, no induction of CX3CL1 mRNA was observed 
in HUVECs following treatment with IS alone. These findings reveal that the proinflammatory cytokine milieu, 
including TNF-α, produced by IS-stimulated monocytes is capable of inducing increased secretion of CX3CL1 by 
HUVECs. Moreover, the production of CX3CL1 may result in the selective recruitment of immune cells express-
ing CX3CR1, the chemokine receptor for CX3CL1.
ESRD patients have higher numbers of CD4+CD28− T cells preferentially expressing 
CX3CR1. In agreement with the previous reports11, 12, ESRD patients exhibited markedly expanded CD28− 
cells in the CD4+, but not in the CD8+, T cell compartment (Fig. 5A; p < 0.01 and p = 0.10, respectively). These 
expanded CD4+CD28− cells in ESRD patients were attributable to significant accumulation of the CD45RA+ 
effector memory (EM) subset, which is comprised of terminally-differentiated cells. These cells arise through 
extensive cell divisions caused by repeated stimulation and are characterized by loss of co-stimulatory molecules, 
such as CD27, and gain of inhibitory, immune-regulatory molecules (Supplementary Fig. 8A and B)37, 38. In addi-
tion, CD4+CD28− T cells exhibit a phenotype typical of dysfunctional senescent T cells that have experienced 
extensive cell divisions, including gains of CD57 and CD85j, and a loss of the IL-7 receptor α chain (Suppl. 
Fig. 8C). ESRD patients had significantly higher levels of serum TNF-α compared to healthy controls (Suppl. 
Fig. 4). Moreover, IS-treated monocytes produced an enhanced amount of TNF-α (Fig. 1D and C). Repeated 
antigenic stimulation under TNF-α exposure causes loss of CD28 on CD4 T cells under chronic inflammatory 
Figure 2. Indoxyl sulfate (IS) is a potent agonist for the AhR on human monocytes. (A) Purified monocytes 
from HCs were treated with IS at the indicated concentration for 24 hr, and the expression of AhR responsive 
genes CYP1A1 (left panel) and CYP1B1 (right panel) were analyzed by real-time RT-PCR. TCDD was used as a 
positive agonist control. (B) Western blot analysis of AhR in monocytes freshly isolated from peripheral blood 
of HCs (n = 3). (C) CD14+ monocytes were freshly isolated from ESRD patients (n = 4) and age-matched HCs 
(n = 4) and the expression of AhR mRNA was analyzed by real-time RT-PCR. (D) Monocytes isolated from 
healthy controls were treated with 30% (v/v) of the indicated sera for 24 hr and CYP1B1 mRNA expression 
was analyzed by real-time RT-PCR. Expression of β-actin was used as a normalization control (A, C and D). 
Bar graphs show the mean ± SEM of five (A) or four (D) independent experiments. *p < 0.05: compared to no 
treatment group and HCs by two-tailed paired (A and D) and unpaired t-test (C), respectively.
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Figure 3. IS-induced TNF-α expression is regulated through AhR activation in human monocytes. Monocytes 
were co-treated with IS and AhR antagonists, α-NF or GNF351, at the indicated concentration for 24 or 48 hr. 
(A and B) At 24 hr post-treatment, TNF-α mRNA expression was analyzed by real-time RT-PCR. (C) At 48 hr 
post-treatment, the amount of TNF-α in the culture supernatant was quantified by ELISA. Two representative 
experiments of five are shown. (D) At 24 hr post-treatment, CYP1B1 mRNA expression was analyzed by real-
time RT-PCR. Expression of β-actin was used as a normalization control. (E and F) Sera were pooled from 
patients with the top 10 (IShigher-ESRD) IS serum concentrations. As a control, sera from healthy controls were 
pooled. Monocytes isolated from healthy controls were treated with 30% (v/v) of the indicated sera for 24 hr 
with or without 1 μM of GNF351. Gene expression levels were analyzed by real-time RT-PCR. (G) Knockdown 
efficiency of AhR. Freshly purified total monocytes were transfected with AhR-specific or control siRNA 
(20 pmol of both siRNAs). AhR mRNA expression was analyzed at 24 hr after transfection by real-time RT-
PCR. (H and I) siRNA transfected monocytes were treated with IS for 24 hr. Real-time RT-PCR was performed 
for analysis of TNF-α and CYP1B1 mRNA expression. Expression of β-actin was used as a normalization 
control. Bar graphs show the mean ± SEM of five (A) or four (B and D) or six (E–I) independent experiments. 
*p < 0.05, **p < 0.01, and ***p < 0.001 by one way ANOVA (A,B and D) and by two-tailed paired t-test (E–I), 
respectively.
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conditions39. Therefore, highly purified CD4+CD28+ T cells from ESRD patients were stimulated with anti-CD3/
CD28 mAbs and cultured with recombinant human TNF-α for 28 days. In this long-term culture system, a sig-
nificant increase in CD4+CD28− T cells was found in the TNF-α treatment group after 28 days (Fig. 5B). To 
emphasize the link between IS-activated monocytes and the generation of CD4+CD28− T cells, CD4+CD28+ 
naive T cells were stimulated with anti-CD3/CD28 mAbs for 3 days and co-cultured with IS-treated monocytes 
for another 25 days. A significant increase in CD4+CD28− T cells was found after 21 days in the co-culture with 
IS-activated monocytes which produce a higher TNF-α (Fig. 5C). These data suggest that the TNF-α rich envi-
ronment in ESRD patients leads to an accumulation of circulating CD4+CD28− T cells.
The findings in Fig. 4 prompted us to examine whether ESRD patients have a higher frequency of immune 
cells expressing CX3CR1, the receptor for CX3CL1, and to determine which cell subsets express CX3CR1. Of 
note, CX3CR1 was predominantly expressed on CD4+CD28− T cells, but not on CD4+CD28+ T cells, suggesting 
that the increased frequency of the CX3CR1+ subset in CD4 T cells is secondary to the significant accumulation 
of CD4+CD28− T cells in ESRD patients (Fig. 5D). Flow cytometric analysis showed that the frequency of CD4+ 
T cells expressing CX3CR1 in ESRD patients was augmented more than two-fold over that of HCs (7.41 ± 1.59 
vs. 3.21 ± 0.45; p < 0.04) (Fig. 5E). Moreover, the mutually exclusive expression pattern of CD28 and CX3CR1 in 
CD4 T cells was confirmed by the finding that the percentage of CD4+CD28− T cells in ESRD patients correlates 
significantly with the percentage of CD4+CX3CR1+ T cells (Fig. 5F; p < 0.001).
Figure 4. TNF-α markedly upregulates CX3CL1 production by HUVECs. (A) HUVECs were stimulated 
with TNF-α (5 ng/ml) up to 8 hours and CX3CL1 mRNA expression was analyzed by real-time RT-PCR at 
the indicated time-points. (B) HUVECs were treated with various concentrations of TNF-α (1 to 10 ng/ml) 
for 4 hours, and the expression of CX3CL1 was analyzed by real-time RT-PCR. (C) HUVECs were stimulated 
with various concentrations of TNF-α (1 to 10 ng/ml) for 18 hours and the amount of CX3CL1 in the culture 
supernatant was quantified by conventional ELISA. (D) Purified monocytes were treated with or without IS 
for 48 hr, and the supernatant (MCM: monocyte-conditioned media) of each culture was harvested. Control or 
IS-treated monocyte-conditioned media (Con- or IS-MCM) was added to confluent, cultured HUVECs in the 
presence of anti-TNF-α Ab or control IgG, followed by a 4 hr incubation. CX3CL1 mRNA expression in treated 
HUVECs was analyzed by real-time RT-PCR. Expression of β-actin was used as a normalization control. Bar 
graphs show the mean ± SEM of three to four independent experiments. *p < 0.05 and **p < 0.01: compared to 
no TNF-α treatment group by two-tailed paired t-test (B and C).
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Figure 5. CD4+CD28− T cells expressing CX3CR1, a receptor for CX3CL1, are expanded under the TNF-α 
rich environment in ESRD patients. (A) Frequencies (%) of CD28− cells in CD4+ and CD8+ T cells in ESRD 
patients (n = 50) and age-matched HCs (n = 28). (B) Purified CD4+CD28+ cells from ESRD patients were 
stimulated with α-CD3/CD28 Ab-coated beads and IL-2 in the absence or presence of TNF-α. At 4 days, beads 
were removed using a magnet and the cytokines were re-supplemented every 3–4 days. CD28 expression was 
analyzed every 7 days by flow cytometry. Representative FACS plot of change in CD28 expression on cultured 
CD4+CD28+ T cells in ESRD patients under indicated culture conditions (Left). On the indicated day, cultured 
cells were harvested and the frequency of CD28− cells was determined by flow cytometry (n = 4) (Right). (C) 
Purified naive CD4+ T cells were stimulated with α-CD3/CD28 Ab-coated beads and IL-2. At 4 days, beads 
were removed using a magnet and the cell were co-cultured with monocytes, which were stimulated with IS 
(1,000 μM) for 24 hr. IS-stimulated CD14+ monocytes were re-supplemented every 3–4 days. CD28 expression 
was analyzed every 7 days by flow cytometry. Representative FACS plot of change in CD28 expression on 
cultured naive CD4+ T cells under indicated culture conditions (Left). On the indicated day, cultured cells 
were harvested and the frequency of CD28− cells was determined by flow cytometry (n = 3) (Right). (D) 
Representative contour plot of CX3CR1 expression on CD4+CD28+ and CD4+CD28− T cells from ESRD 
patients and HCs (E) Expanded CX3CR1+CD4+ T cells in patients with ESRD compared with HCs. (F) 
Frequency (%) of CX3CR1+ cells positively correlates with the frequency of CD28− cells in CD4+ T cells of 
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To investigate the functional role of CX3CR1 expressed on CD4+CD28− T cells, a transwell chemotaxis assay 
using recombinant CX3CL1 was performed with CD4 T cells derived from ESRD patients (Fig. 5G). The results 
clearly demonstrate that the frequency of migrating CD4+CD28− T cells significantly increased up to the 10 ng/
ml concentration of CX3CL1, indicating that T cells expressing CX3CR1 were preferentially recruited by recom-
binant CX3CL1.
Taken together, CD4+CD28− T cells, which are greatly expanded under TNF-α-rich conditions in ESRD 
patients, preferentially express CX3CR1 conferring the unique ability to migrate toward CX3CL1 produced by 
activated vascular endothelial cells.
CD4+CD28− T cells have cytotoxic and senescent features that induce endothelial cell dam-
age. Our data show that TNF-α-stimulated human endothelial cells produce a considerable level of CX3CL1, 
which selectively recruits CD4+CD28− T cells expressing CX3CR1. To investigate whether these CD4+CD28− T 
cells have an adverse effect on vascular endothelial cells, HUVECs were stimulated with IFN-γ for 48 hours to 
induce MHC class II on their surface and were then co-cultured with ESRD patient-derived CD4+CD28− T 
cells and CD4+CD28+ T cells in the presence of superantigen to crosslink TCR and MHC class II. Damage to 
co-cultured HUVECs was evaluated using the TUNEL apoptosis assay. As seen in Fig. 6A and B, the frequency 
of apoptotic HUVECs increased when co-cultured with CD4+CD28− T cells compared with CD4+CD28+ T 
cells, suggesting that CD4+CD28− T cells have the potential to invade and harm human endothelial tissue. 
Several human studies have suggested that cytotoxic CD4+ T cells are characterized by a loss of CD27 and CD28 
surface expression and concomitant gain of CD57. Indeed, this phenomenon was also observed as shown in 
Supplementary Fig. 8C 40. In addition, in ESRD patients the expanded CD4+CD28− T cells had significantly 
higher levels of cytotoxic granules, such as granzyme B and perforin, than CD4+CD28+ T cells had (Fig. 6C 
and D). Flow cytometric analysis revealed that CD4+CD28− T cells predominantly expressed transcription fac-
tors typical of a Th1 profile (Fig. 6C and D), and thus, presumably would express large amounts of IFN-γ and 
TNF-α on activation. Recent studies reported that Eomesodermin (Eomes) plays a critical role in the develop-
ment of long term memory and cytotoxic CD4 T cells41, 42. As expected by Figs 5F and 6D, both CX3CR1+ and 
CD4+CD28− T cells in ESRD patients had a significantly higher Eomes expression compared with each coun-
terpart subset (Fig. 6E and F). Our data suggest that the increased CD4+CD28− T cells in ESRD patients display 
cytotoxic features suggesting they are capable of inducing endothelial cell damage.
Discussion
In the present study, we demonstrate ESRD-related alterations of monocytes and CD4 T cells in patients and their 
putative pathogenic roles for endothelial damage, which is a critical step for the development and accelerated 
progression of CVD in patients with ESRD. In vitro culture data clearly demonstrate that IS, a key uremic toxin, 
functions as an endogenous stimulus that cause monocytes to produce augmented amounts of TNF-α through 
the AhR-mediated pathway. Further, stimulation with TNF-α leads to production of copious amounts of CX3CL1 
by human vascular endothelial cells and gradual loss of CD28 molecules by CD4 T cells under TCR stimulation. 
Of note, CD4+CD28− T cells, the predominantly accumulated cell type in peripheral blood of ESRD patients, 
preferentially express CX3CR1, a chemokine receptor for CX3CL1. These CD4+CD28− T cells possess cytotoxic 
capability when activated including the ability to induce apoptosis of human endothelial cells, as well as the ability 
to preferentially migrate in response to CX3CL1 (Fig. 7).
ESRD is associated with significant increases in cardiovascular disease, which accounts for considerable mor-
bidity and mortality and may be induced by the uremic proinflammatory milieu43. Uremia accompanying chronic 
renal failure has a profound impact on the immune system including increased numbers, composition, and func-
tions of various immune cells2, 3, 44. In ESRD patients, uremia mediates a vicious cycle between oxidative stress and 
the inflammatory immune response exacerbating a chronic proinflammatory milieu, which exerts detrimental 
effects on both the innate and adaptive immune systems and consequently increases the risk of atherosclerotic 
disease8. However, the mechanisms underlying uremic toxin-mediated immune dysfunction and its pathogenic 
roles are still unclear.
In agreement with a previous report1, our data clearly show expansion of CD16+ monocytes in ESRD patients 
(Suppl. Fig. 1). CD16+ monocytes play a pivotal role in the pathophysiology of many inflammatory diseases45. 
Considering that CD14+CD16+ monocytes potently induce TNF-α, IL-1β, and IL-6 in response to various stim-
uli46, expanded CD14+CD16+ monocytes in ESRD patients might contribute to the generation of the proin-
flammatory milieu. Moreover, CD14dimCD16+ monocytes have the unique ability to patrol the blood vessel 
endothelium for signs of damage and infection46.
As seen in Fig. 1A, serum levels of the endogenous uremic toxins IS and PCS are dramatically elevated due to 
inadequate renal clearance in patients with CKD (102.44 ± 6.26 μM and 185.41 ± 14.99 μM, respectively) com-
pared with healthy individuals (1.87 ± 0.21 μM and 15.04 ± 4.70 μM, respectively)47. Furthermore, these toxins 
ESRD patients (n = 46). Each data point represents an individual subject. (G) Freshly-purified CD4+ memory 
T cells from ESRD patients were stained with APC-conjugated anti-CD28 mAb and a chemotaxis assay was 
performed at various concentrations of CX3CL1 (0 to 10 ng/ml) for 2 hours using a transwell system. The 
frequency (%) of CD28− T cells in migrated cells at various concentrations of CX3CL1 was analyzed by flow 
cytometry. Bar graphs show the mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.005 by two-tailed unpaired 
t-test (A and E) or 2 way ANOVA test (B and C). P value in (F) was obtained using the Pearson correlation 
analysis. Box plots displaying medians, 25th and 75th percentiles as boxes, and minimum and maximum values 
as whiskers (n = 6). *p < 0.05 by two-tailed paired non-parametric test (G).
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Figure 6. CD4+CD28− T cells have features typical of cytotoxic T cells and induce death in HUVECs in 
response to TCR stimulation. (A) Activated CD4+CD28− T cells induce death of HUVECs. HUVECs were pre-
treated with IFN-γ (2,000 U/ml) for 48 hours and co-cultured with purified CD4+CD28− T cells or CD4+CD28+ 
T cells in the presence of superantigen, SEB (10 ng/ml), and TSST-1 (10 ng/ml) for TCR stimulation. The level of 
cell death was analyzed by TUNEL assay. The nuclei in TUNEL+ apoptotic cells were detected by TMR (red) and 
DAPI (blue) was used for nuclei staining of HUVECs. Data is representative of four independent experiments. 
At least three images were analyzed in each group. Scale bar equals 100 μm. (B) Frequencies (%) of apoptotic 
cells among three treatment groups. (C) Representative histogram plot of cytotoxic granules (perforin and 
granzyme B) and transcription factors (GATA3 and T-bet) in CD4+CD28+ and CD4+CD28− T cells from ESRD 
patients. (D) MFIs (mean fluorescent intensities) of cytotoxic granules and transcription factors were compared 
between CD4+CD28+ and CD4+CD28− T cells (n = 11) (E) Representative histogram plot (Left panel) and 
MFIs (Right panel) of transcription factors, Eomes and T-bet in CX3CR1+ and CX3CR1− CD4+ T cells from 
ESRD patients (n = 5). (F) Representative histogram plot (Left panel) and MFIs (Right panel) of Eomes in 
CD4+CD28+ and CD4+CD28− T cells from ESRD patients (n = 5). *p < 0.05, **p < 0.01 and ***p < 0.005 by 
two-tailed paired t-test.
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cannot be efficiently removed by hemodialysis due to their strong binding capacity for serum proteins48. Many 
in vitro experiments have demonstrated that IS and PCS harm endothelial cells and vascular smooth muscle 
cells in chronic kidney disease and also inhibit proliferation and wound repair of vascular endothelial cells49. 
However, due to their constant exposure, immune cells may also be major targets of these toxins. In fact, in a 
mouse model it has been found that IS stimulates macrophage function and enhances inflammatory responses 
associated with LPS50. Furthermore, diminished serum concentrations of IS due to treatment with AST-120, an 
orally-administered intestinal sorbent, lessens monocyte inflammation and attenuates the progression of ather-
osclerosis in a CKD animal model34. In the present study, we demonstrate that monocytes preferentially respond 
to IS and secrete increased amounts of the proinflammatory cytokine TNF-α (Fig. 1D). Clinically, endogenous IS 
diluted in 30% patient serum is sufficient to induce TNF-α mRNA in monocytes derived from healthy controls. 
Therefore, IS may be responsible for elevated serum TNF level in patients with ESRD (Suppl. Fig. 4 and Fig. 1E). 
IS was recently identified as a potent endogenous ligand for the aryl hydrocarbon receptor (AhR)32. AhR was 
initially known as the dioxin receptor and is a ligand-activating transcription factor involved in biological detox-
ification responses against a variety of ligands including environmental pollutants51–54. However, recent studies 
demonstrated that there are many naturally occurring AhR ligands such as tryptophan derivatives (e.g. indoxyl 
sulfate)51, 53. Given the potential involvement of tryptophan-derived uremic toxins and AhR-activating pollutants 
in cardiovascular diseases, defining the AhR-mediated pathway is important for understanding pathogenesis of 
cardiovascular diseases51, 55.
Like dendritic cells and macrophages56, circulating human monocytes constitutively express a high level of 
AhR (Fig. 2B). Further, interruption of the AhR-IS interaction using AhR antagonists and AhR siRNA led to a 
significant diminution of TNF-α mRNA and its protein level in human monocytes/macrophages (Fig. 3), clearly 
supporting an important role of AhR-mediated responses in pathogenesis of ESRD patients. A recent study 
reported that TCDD, a potent AhR ligand, induced TNF-α production in a human macrophage cell line via the 
AhR-EGFR-ERK pathway57. However, a negative regulatory role for AhR against LPS-induced inflammatory 
responses of macrophages (but not those induced by other TLR ligands) has also been suggested, as increased 
IL-6 and TNF responsiveness has been demonstrated in AhR knockout, murine macrophages58. Therefore, more 
detailed studies are needed in order to clarify how IS-elicited AhR activation influences production of proinflam-
matory cytokines by circulating monocytes.
Besides overproduction of cytokines, recent studies have shown that uremic monocytes also induced angio-
tensin converting enzyme (ACE) and ROS production, which plays a crucial role in inflammation and progres-
sion of atherosclerosis8, 34, 59, 60. IS-activated monocytes significantly increased ROS production (Suppl. Fig. 6) and 
showed a tendency to increase the expressions of ACE, angiotensin II receptor type 1 and 2 (AT1R and AT2R) 
(data not shown). However, AhR antagonist GNF351 had no effect on IS-mediated ROS production as well as 
ACE, AT1R, and AT2R in primary monocytes (Suppl. Fig. 6 and data not shown), suggesting that different mech-
anisms are involved in these changes and enhanced production of TNF-α by IS-treated monocytes.
The gene signature of vascular endothelial cells is largely changed in the context of the inflammatory cytokine 
milieu61. In particular, TNF-α treatment has been shown to predominantly induce the expression of certain 
chemokine genes, such as CXCL2, CXCL6 and CX3CL1, by HUVECs. These chemokines play crucial roles in 
Figure 7. Proposed model of IS-mediated immune dysfunction provoking endothelial damage in ESRD 
patients. IS, a key uremic toxin which is dramatically accumulated in patients with chronic renal dysfunction, 
induces secretion of TNF-α by human monocytes through the aryl hydrocarbon receptor (AhR). Upon 
stimulation with TNF-α, human endothelial cells predominantly produce CX3CL1, a specific chemokine ligand 
of CX3CR1, which is highly expressed on CD4+CD28− T cells. ESRD patients have a markedly higher frequency 
of circulating cytolytic CD4+CD28− T cells, which are significantly expanded under chronic exposure to TNF-
α. These CD4+CD28−CX3CR1+ T cells are preferentially recruited by CX3CL1 and induce apoptosis of human 
endothelial cells upon TCR activation.
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leukocyte recruitment toward sites of inflammation62. Consistent with previously-reported microarray data62, 
our data show that TNF-α markedly induces production of CX3CL1 by HUVECs (Fig. 4). Of note, CX3CR1, the 
chemokine receptor for CX3CL1, is predominantly expressed by CD4+CD28− T cells, which are greatly expanded 
in ESRD patients (Fig. 5A and D). In addition, we show CD4+CD28− T cells possess a unique capability to 
migrate toward activated vascular endothelial cells producing CX3CL1 (Fig. 5G). The accumulation of CD28− T 
cells, mainly CD8 T cells and to a lesser degree CD4 T cells, was initially regarded as an age-related change (so 
called immunosenescence)37; however, recent studies have demonstrated that age-inappropriate expansion of 
CD4+CD28− T cells also occurs in patients with autoimmune disorders and in patients at risk for inflammatory 
vascular complications. This suggests that these cells might contribute to disease pathogenesis63. A major cause of 
CD28 loss in T cells is replicative senescence caused by repeated antigenic stimulation, although CD28 expression 
is also gradually lost when cells are exposed to the proinflammatory cytokine milieu37, 38, 63. Of interest, chronic 
exposure to TNF-α leads to downregulation of the CD28-specific initiator complex, resulting in decreased CD28 
expression on CD4+ T cells64, 65. Therefore, TNF-α blocking agents have been considered as possible therapeutics 
to diminish pathogenic CD4+CD28− T cells in rheumatoid arthritis63. Since repeated antigenic stimulation leads 
to chronic inflammation, making proinflammatory cytokines such as TNF-α abundant, loss of CD28 due to both 
replicative senescence and cytokine exposure might not be mutually exclusive in inflammatory disorders. In this 
context, it should be noted that IS markedly increased monocyte TNF-α and IL-1β production as shown in our in 
vitro culture data (Fig. 1D and Suppl. Fig. 2A and B), and CD4+CD28− T cells in ESRD have immunophenotypes 
typical of senescent T cells, such as gain of CD57 and CD85j and loss of IL-7Rα, indicating that they have under-
gone extensive cell division (Suppl. Fig. 8C). More importantly, chronic exposure to TNF-α allows for gradual loss 
of CD28 expression on TCR-stimulated, purified CD4+CD28+ T cells from ESRD patients (Fig. 5B and C). Thus, 
this could be one mechanism for expansion of CD4+CD28− T cells in patients with ESRD.
Senescent CD4+CD28− T cells possess unique features characteristic of cytotoxic cells (like CD8+ T cells) 
(Fig. 6C and D)11, 66, recruitment of these cells by CX3CL1 likely results in damage to the vascular endothelium 
via induction of apoptosis (Fig. 6A and B). Indeed, CD4+CD28− T cells were reported to be a major T cell subset 
observed among infiltrating cells at sites of inflammation and were found to be associated with atherosclerosis, 
suggesting that CD4+CD28− T cells take part in vascular plaque destabilization22.
Taken together, the findings presented in this study demonstrate that IS, a major uremic toxin, induces TNF-α 
production in monocytes through AhR pathway and an increased TNF-α is involved with the expansion of 
CD4+CD28− T cells and their recruitment to activated vascular endothelial cells. These changes critically affect 
the pathogenesis of cardiovascular diseases in ESRD. Thus, this suggests that IS-mediated immune dysfunction is 
an important contributor to the development and progression of CVD in patients with ESRD.
Methods
Human subjects and cell isolation. The study protocols were approved by the institutional review board 
of Seoul National University Hospital and Severance Hospital. Peripheral blood of ESRD patients and healthy 
controls (HCs) was drawn after obtaining written, informed consent. The methods were performed in accord-
ance with the approved guidelines. Peripheral blood mononuclear cells (PBMC) were isolated from blood by 
density gradient centrifugation (Bicoll separating solution; BIOCHROM, Cambridge, UK). Total monocytes 
were negatively separated from PBMC with pan-monocyte microbeads (Miltenyi Biotec, Auburn, CA), if no 
special mention in the figure legend. Total CD4+ T cells and CD4+ memory T cells were negatively enriched from 
PBMC using human CD4 T cell enrichment kit and human memory CD4 T cell enrichment kit (STEMCELL 
Technologies, Vancouver, Canada), respectively. CD4+CD28+ and CD4+CD28− T cells were separated from 
CD4+ memory T cells using a human CD28 microbead kit (Miltenyi Biotec) as described in user’s instructions. 
CD28− cells were retained in the run-through fraction including CD28 unlabeled cells.
Flow cytometric analysis. The following antibodies were used for flow cytometric analysis: 
Anti-Perforin-Alexa fluor 488, anti-CD28-allophycocyanin (APC), anti-CD19-APC, anti-CD3-APC, 
anti-CD56-APC, anti-CD3-APC-cyanin7 (Cy7),  anti-CD8-APC-Cy7, anti-CD14-APC-Cy7, 
anti-CD14-fluorescein isothiocyanate (FITC), anti-HLA-DR-FITC, anti-CD16-R-phycoerythrin (PE), 
anti-GATA3-PE, anti-CD45RA-PE-cyanin 5 (Cy5), anti-CD4-PE-Cy5, anti-CD16-PE-Cy5, anti-CCR7-PE-Cy7, 
anti-CD4-PE-Cy7, anti-CD4-V450, anti-GranzymeB-V450, anti-CD8-V500, anti-CD3-V500 (all from 
BD Bioscience, Franklin Lakes, NJ), anti-CD57-FITC, anti-CD4-FITC, anti-CD85j-PE, anti-CX3CR1-PE, 
anti-T-bet-PE-Cy7, anti-Eomes-Peridinin chlorophyll (PerCP)-efluor710 (six from eBioscience, San Diego, CA), 
anti-HLA-DR-PE-Cy5, anti-IL-7Rα-V450, anti-CD57-V450 (three from BioLegend, San Diego, CA), anti-CX-
3CR1-FITC (MBL International Corporation, Woburn, MA). For intracellular staining of T cell lineage-specific 
transcription factors (T-bet, Gata3, and Eomes), granzyme B and perforin, PBMC were fixed and permeabilized 
with Fix/Perm buffer set (BioLegend). Stained cells were acquired by a BD LSRFortessa (BD bioscience) and ana-
lyzed by using FlowJo software (ver. 9.0 or 10.0; Tree Star, OR).
Measurement of indoxyl sulfate and p-cresyl sulfate in human plasma. Simultaneous quantifica-
tion of indoxyl sulfate and p-cresyl sulfate in human plasma were analyzed using liquid chromatography–tandem 
mass spectrometry (LC–MS/MS)67. In brief, plasma samples (25 μl) were prepared by protein precipitation with 
225 μl of internal standard solution (indoxyl sulfate_d4, 100 ng/ml in 100% acetonitrile) followed by centrifuga-
tion at 19,500 × g for 10 min at 4 °C. The supernatant (20 μl) was mixed with 980 μl of distilled water and 3 μl was 
injected into a Kinetex 2.6 μm C18 column (2.1 × 100 mm, Phenomenex, USA). The mobile phase consisted of 
solvent (A) 5 mmol/L ammonium acetate solution and solvent (B) 100% methanol. The flow rate was 0.2 ml/min 
with a total cycle time of 12 min/sample. The initial gradient condition was 20% B (8/2, v/v) for 1 min followed 
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by a linear gradient up to 60% B over the next 1.5 min, followed by 95% B over the next 0.5 min. It was returned 
to 20% B over the next 0.5 min, followed by 20% B for 9 min. Indoxyl sulfate and p-cresyl sulfate were eluted at 
1.97 min and 3.45 min, respectively. The calibration standards for indoxyl sulfate and p-cresyl sulfate were linear 
over the range of 0.2 to 50 μg/ml and 0.4 to 80 μg/ml, respectively. The human blank plasma was treated with 
active charcoal to eliminate endogenous metabolites. Selected reaction monitoring analysis was performed using 
a triple quadrupole mass spectrometer (API4000, AB SCIEX, Foster City, CA, USA) equipped with an ESI source. 
Indoxyl sulfate and p-cresyl sulfate were detected at m/z 211.921 → 79.700, 186.947 → 106.900, respectively, in 
multiple reactions monitoring positive mode.
Cell culture. Purified monocytes and CD4+ T cells derived from HCs were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 μg/ml streptomy-
cin, and 2 mM L-glutamine. Monocytes were seeded at 5 × 105 into polypropylene round bottom tubes (BD 
Bioscience) in the presence of various concentrations of IS (Sigma-Aldrich, St. Louis, MO). In some experiments, 
monocyte-conditioned media (MCM) was prepared after incubation for 48 hr with IS. For experiments using 
pooled uremic serum, purified monocytes were incubated for 24 hr with pooled serum from ESRD patients or 
age-matched HCs. The cells and supernatant were harvested for further analysis.
HUVECs, human umbilical vein endothelial cells, were purchased from Lonza (Basel, Switzerland) and were 
grown adherent to 0.1% gelatin-coated cell culture dishes (Welgene, Gyeongsan-shi, Republic of Korea) with 
EGMTM-2 basal medium (Lonza) supplemented with 2% fetal bovine serum (FBS), 0.4% hFGF-β, 0.1% hEGF, 
VEGF, R3-IGF-1, ascorbic acid, heparin, gentamicin/amphotericin-B, and 0.04% hydrocortisone. HUVECs were 
seeded at 0.1% on a gelatin-coated six well, flat-bottom plate (BD Bioscience) and stimulated with recombinant 
human TNF-α (1 to 10 ng/ml; R&D systems) or recombinant human IL-1β (10 ng/ml; R&D systems) for the 
indicated time periods.
For long term in vitro culture of CD4 T cells, purified CD4+CD28+ T cells were stimulated with anti-CD3/
CD28 Ab coated beads (Dynabeads® T-Activator CD3/CD28; Thermo Fisher Scientific, Waltham, MA) and IL-2 
(50 U/ml; PeproTech, Rocky Hill, NJ) in the absence or presence of TNF-α (10 ng/ml; R&D systems, Minneapolis, 
MN). At 4 days, beads were removed using a magnet and the cytokines were re-supplemented every 3–4 days. 
CD28 expression was assessed every 7 days using a BD LSRFortessa.
Transfection of AhR-targeted siRNA. Purified primary total monocytes were transfected with siRNA of 
AhR or negative control (NC) (Dhamacon, SMART pool ON-TARGET plus human AhR siRNA or non-targeting 
siRNA) using lipofectamine imax (Invitrogen). After 24 hr, the cells were treated with IS for another 24 hr.
Enzyme-linked immunosorbent assay (ELISA). The amounts of TNF-α and IL-1β in culture super-
natants of IS-treated monocytes were quantified using commercial human ELISA kits (Both from eBioscience). 
The amount of CX3CL1 produced by TNF-α-treated HUVECs was quantified in the culture media using human 
CX3CL1/Fractalkine ELISA kit (R&D systems). The measurement of OD (Optical density value) was performed 
by Infinite M200 (Tecan, Männedorf, Switzerland).
Quantitative RT-PCR. cDNA was synthesized from total RNA, and real-time quantitative 
RT-PCR was performed in triplicate on a 7500 PCR system (Applied Biosystems by Life Technologies 
Corp, Waltham, MA) using the SensiFAST SYBR® No-ROX (Bio-line, London, UK) as previ-
ously described21. The sequences of the sense and antisense primers used in this study were as fol-
low; TNF-α :  5 ′-AGCCCATGTTGTAGCAAACC-3 ′  and 5 ′-TGAGGTACAGGCCCTCTGAT-3 ′ ; 
IL-1β: 5′-CACGATGCACCTGTACGATCA-3′ and 5′-GTTGCTCCATATCCTGTCCCT-3′; CX3CL1: 
5′-TCCTTACCAGCAGAGCACCT-3′, 5′-GTCTCTGCTCTGCCCATTTC-3′; AhR: 5′-CCG TGT CGA TGT 
ATC AGT GC-3′ and 5′-GCC TGG CAG TAC TGG ATT GT-3′; CYP1A1: 5′-TCTTCCTTCGTCCCCTTCAC-3′ 
and 5′-TGGTTGATCTGCCACTGGTT-3′ and CYP1B1: 5′-TGCCTGTCACTATTCCTCATGCCA-3′ and 
5′-ATCAAAGTTCTCCGGGTTAGGCCA-3′; and β-actin: 5′-GGACTTCGAGCAAGAGATGG-3′ and 
5′-AGCACTGTGTTGGCGTACAG-3′. The levels of gene expression were normalized to the expression of 
ACTINB. The comparative CT method (ΔΔCT) was used for the quantification of gene expression.
Western blot analysis. Cell lysates were prepared from freshly-isolated monocytes. To analyze the expres-
sion of AhR in these cells, whole cell lysates were separated on an 8% SDS-polyacrylamide gel and blotted onto a 
polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA), The membrane was incubated overnight 
at 4 °C with rabbit anti-human AhR polyclonal Ab (Cell Signaling Technology), followed by incubation with the 
HRP-conjugated secondary Ab for 1 hour. The membranes were developed by SuperSignal West Femto Maximum 
Sensitivity substrate kit (Thermo scientific, Waltham, MA).
Chemotaxis assay. Purified CD4+ memory T cells derived from ESRD patients were stained with 
anti-CD28-APC (BD Biosciences) for 30 min at 4 °C. Chemotaxis of stained CD4+ memory T cells was analyzed 
using 24-well Transwell chambers with 5 μM pores (Corning Inc, Corning, NY). 3 × 105 cells in 100 μl chemotaxis 
buffer (RPMI 1640 with 0.5% BSA) were placed in the upper chambers. Recombinant human CX3CL1 (2.5 to 
20 ng/ml; R&D systems) in 600 μl chemotaxis buffer was placed in the lower wells and the chambers were incu-
bated for 2 hours at 37 °C and 5% CO2. Migrated cells located in the bottom wells were collected and analyzed 
using a BD LSRFortessa.
TUNEL assay. HUVECs were stimulated with recombinant human IFN-γ (2,000 U/ml; eBioscience) for 
48 hours to induce MHC Class II expression. The medium was removed and EBM-2 complete medium added in 
the presence of superantigens, SEB (10 ng/ml) and TSST-1(10 ng/ml; both from Toxin technology, Sarasota, FL). 
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After 1 hour of loading with superantigens, CD4+CD28− or CD4+CD28+ T cells were added to the HUVECs and 
were co-cultured for 4 hours. Apoptotic HUVECs following co-culture with CD4+CD28− T cells were detected 
using the In Situ Cell Death Detection Kit, TMR red (Roche, Indianapolis, IN) as described in the instructions. 
The red apoptotic cells were visualized on a fluorescence microscope using the Leica DMI6000B (Leica camera, 
Wetzlar, Germany).
Statistical analysis. A two-tailed paired or unpaired student’s t-test was done to analyze data using Graph 
Pad Prism 5 (GraphPad Software, La Jolla, CA) and Microsoft Excel 2013. P values of less than 0.05 were consid-
ered statistically significant.
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